Abstract
Background Oral cavity cancer (OCC) is one of the most common carcinoma diseases. Recent genome-wide association studies (GWAS) have reported numerous genetic variants associated with OCC susceptibility. However, the regulatory mechanisms of these genetic variants underlying OCC remain largely unclear.
Objective This study aimed to identify OCC-related genetics risk genes contributing to the prognosis of OCC.
Methods By combining GWAS summary statistics (N = 4,151) with expression quantitative trait loci (eQTL) across 49 different tissues from the GTEx database, we performed an integrative genomics analysis to uncover novel risk genes associated with OCC. By leveraging various computational methods based on multi-omics data, risk genes were prioritized as promising candidate genes for drug repurposing in OCC.
Results Using two independent computational algorithms, we found that 14 risk genes whose genetics-modulated expressions showed a notable association with OCC. Among them, nine genes were newly identified, such as IRF4 (P = 2.5×10-9 and P = 1.06×10-4), TNS3 (P = 1.44×10-6 and P = 4.45×10-3), ZFP90 (P = 2.37×10-6 and P = 2.93×10-4), and DRD2 (P = 2.0×10-5 and P = 6.12×10-3).
These 14 genes were significantly overrepresented in several cancer-related terms, and 10 of 14 genes were enriched in 10 potential druggable gene categories. Based on differential gene expression analysis, the majority of these genes (71.43%) showed remarkable differential expressions between OCC patients and paracancerous controls. Integration of multi-omics-based evidence from genetics, eQTL, and gene expression, we identified that the novel risk gene of IRF4 exhibited the highest ranked risk score for OCC. Survival analysis showed that dysregulation of IRF4 expression was significantly associated with cancer patients outcomes (P = 8.1×10-5).
Conclusions In summary, we prioritized 14 OCC-associated genes with nine novel risk genes, especially the IRF4 gene, which provides a drug repurposing resource to develop therapeutic drugs for oral cancer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by National Natural Science Foundation of China (No. 81970956 to M.W.), and the Scientific Research Foundation for Talents of Wenzhou Medical University (KYQD20201001 to Y.M.). The funders had no role in the designing and conducting of this study and collection, analysis, and interpretation of data and in writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://gwas.mrcieu.ac.uk/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the GWAS summary statistics on oral cancer applied in the present analysis can be obtained from the MRC Integrative Epidemiology Unit (IEU) database (https://gwas.mrcieu.ac.uk/, accession ID: ieu-b-94). The GTEx eQTL data (version 8) were gained from the Zenodo repository (https://zenodo.org/record/3518299#.Xv6Z6igzbgl). The 1,000 Genomes Project European Phase 3 reference panel was downloaded from the IGSR: The International Genome Sample Resource (https://www.internationalgenome.org/category/phase-3/).
Abbreviations
- OCC
- Oral cavity cancer
- GWAS
- Genome-wide association study
- eQTL
- expression quantitative loci trait
- sQTL
- splicing quantitative loci trait
- SNP
- Single nucleotide polymorphism
- CC
- Cellular component
- MF
- Molecular function
- BP
- Biological process
- IEU
- Integrative Epidemiology Unit
- INHANCE
- International Head and Neck Cancer Epidemiology Consortium
- OR
- Odds ratio
- MAGMA
- the Multi-marker Analysis of GenoMic Annotation
- LD
- Linkage disequilibrium
- FDR
- False discovery rate
- WebGestalt
- WEB-based Gene SeT AnaLysis Toolkit
- GO
- Gene Ontology
- PPI
- Protein-protein interaction
- GEO
- the database of Gene Expression Omnibus
- TCGA
- The Cancer Genome Atlas.
